anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a cholagogue containing costunolide as an active component. CONSTITUTION:The objective cholagogue contains costunolide of formula which is a component of saussureae radix (root of Saussurea lappa, a plant of Compositae family) as an active component. The compound of formula can be prepared by treating saussureae radix with acetone, and fractionating the extract by silica gel column chromatography. It is not necessary to separate and purify the costunolide, and the acetone extract may be used as it is. It is administered orally at a dose of 50-100mg/dose in terms of costunolide and 2-3 doses per day. EFFECT:The agent is used as a cholagogue having durable cholagogic effect different from the conventional cholagogue, and exhibiting subsidiary effect for the remedy of ulcer caused by stress.
Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
Canrenone, a major (and active) metabolite of spironolactone, appears in human breast milk. Because spironolactone has been found to be tumorigenic in rats, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. If use of the drug is deemed essential, an alternative method of infant feeding should be instituted.

Thiazides are excreted in human milk in small amounts. Thiazides when given at high doses can cause intense diuresis which can in turn inhibit milk production. The use of ALDACTAZIDE during breast feeding is not recommended. If ALDACTAZIDE is used during breast feeding, doses should be kept as low as possible.
The present invention provides a conjugate of haemoglobin and human seralbumin and a preparation method thereof. The hemoglobin is purified by using membrane filtration and ion exchange chromatography. A liquid phase one-step coupling method, a two-step coupling method or a coupling method capable of absorbing protein on a solid phase medium is used for couple the hemoglobin and a human serum albumin. The coupled product is treated by ion exchange chromatography, ultrafiltration and gel filtration chromatography purification. The molecular weight of the prepared coupled product is from 100 to 300KD. The coupled product is the conjugate of 1 to 3 haemoglobins which are already intramolecularly linked or not intramolecularly linked and 1 to 3 persons' serum albumin molecules. A solid phase adsorption method is used for obtaining the conjugate with the ratio of the haemoglobin to the human serum albumin of 1:1. The final product has the good characteristics of blood substitutes.
The invention relates to carrageenan-containing compositions with improved gelling properties, syneresis ≦3.0 wt. % and breaking strength improved by at least 20% compared to the carrageenan-containing starting material. Said composition contains at least 60 wt. % of carrageenan, preferably k-carrageenan, and a hydrocolloid or protein starch or mixtures thereof. The invention also relates to a method for improving the gelling properties of a carrageenan-containing composition, comprising humidifying the starting material, preferably with water, mixing it at elevated temperatures and conditions of high pressures and high shearing strains, and finely cooling the output material before comminuting it. The invention also relates to the use of the composition in nutriment and pharmaceutical formulations, preferably as texturing agent, viscosifier, gelling agent, film forming agent, Theological aid or stabilizer. The compositions have improved gelling consistency, reduced syneresis and accelerated gelation capacity and, in powder form, have excellent dispersing capacity in solutions.
A topical liquid grip lotion is disclosed in multiple embodiments. The topical liquid grip lotion includes embodiments which are longer lasting that prior products and also includes embodiments which are formulated to provide relief from temporary user discomfort or pain that may associated with the underlying activity by the user in areas where the topical lotion is applied. The certain embodiments of the liquid sports grip aid/liquid hand chalk include about 1% lidocaine. In addition to increasing the amount of time of use per application, these embodiments provide a pain reducing agent which can be exceptionally useful for athletes and individuals who experience soreness in their hands, feet, and body when training. Alternative embodiments include formulations are substantially non-irritating due to the topical use of the product, and not intended for ingestion. It is unique that as not only do the embodiments immediately dry hands, feet, and body but can reduce soreness.
The invention researches a Schiff base derivative containing adamantane skeleton ) Is used for synthesizing and researching anti-tumor activity. . The invention takes 1-bromoadamantane as an initial raw material, carries out a Friedel-crafts alkylation reaction under the catalysis of palladium/carbon to generate 1- (4-methoxy-3-methylphenyl) adamantane, then carries out free radical substitution, oxidation reaction and demethylation reaction to obtain 5- (adamantane-1-yl) -2-hydroxybenzaldehyde, and then carries out condensation reaction on the 5- (adamantane-1-yl) -2-hydroxybenzaldehyde and thiosemicarbazide to obtain the target compound. CCK-8 experiments on target compounds show that the target compounds 6a-h and 5-fluorouracil are tested at the concentration of 20 mu M, and the effect of inhibiting HELA and MCF-7 cells by 6g is best, and all the compounds have almost no inhibiting effect on A549. The IC50 value of the target compound is calculated at each concentration, and 6a, 6f and 6g have the smallest IC50 value on HELA and MCF-7 cells and the best inhibition effect. Therefore, the compound can be used for antitumor drugs and is worthy of popularization in medicine.
OBJECTIVE: We hypothesized that patients with amyotrophic lateral sclerosis (ALS) face a dilemma between motivation to live and difficulty in living, and brain-machine interfaces (BMIs) can reduce this dilemma. This study aimed to investigate the present situation of patients with ALS and their expectations from BMIs.
MATERIALS AND METHODS: Our survey design consisted of an anonymous mail-in questionnaire comprising questions regarding the use of tracheostomy positive pressure ventilation (TPPV), motivation to live, anxiety about the totally locked-in state (TLS), anxiety about caregiver burden, and expectations regarding the use of BMI. Primary outcomes were scores for motivation to live and anxiety about caregiver burden and the TLS. Outcomes were evaluated using the visual analogue scale.
RESULTS: Among 460 participants, 286 (62.6%) were already supported by or had decided to use TPPV. The median scores for motivation to live, anxiety about TLS, and anxiety about caregiver burden were 8.0, 9.0, and 7.0, respectively. Overall, 49% of patients intended to use BMI. Among patients who had refused TPPV, 15.9% intended to use BMI and TPPV. Significant factors for the use of BMI were motivation to live (p = .003), anxiety about TLS (p < .001), younger age (p < .001), and advanced disease stage (p < .001).
CONCLUSIONS: These results clearly revealed a serious dilemma among patients with ALS between motivation to live and their anxiety about TLS and caregiver burden. Patients expected BMI to reduce this dilemma. Thus, the development of better BMIs may meet these expectations.
NAROPIN, 5 mg/mL (0.5%), was evaluated for its ability to provide anesthesia for surgery using the techniques of Peripheral Nerve Block. There were 13 studies performed including a series of 4 pharmacodynamic and pharmacokinetic studies performed on minor nerve blocks. From these, 235 NAROPIN-treated patients were evaluable for efficacy. 

NAROPIN was used in doses up to 275 mg. When used for brachial plexus block, onset depended on technique used. Supraclavicular blocks were consistently more successful than axillary blocks. The median onset of sensory block (anesthesia) produced by ropivacaine 0.5% via axillary block ranged from 10 minutes (medial brachial cutaneous nerve) to 45 minutes (musculocutaneous nerve). Median duration ranged from 3.7 hours (medial brachial cutaneous nerve) to 8.7 hours (ulnar nerve). The 5 mg/mL (0.5%) NAROPIN solution gave success rates from 56% to 86% for axillary blocks, compared with 92% for supraclavicular blocks. 

In addition, NAROPIN, 7.5 mg/mL (0.75%), was evaluated in 99 NAROPIN-treated patients, in 2 double-blind studies, performed to provide anesthesia for surgery using the techniques of Brachial Plexus Block. NAROPIN 7.5 mg/mL was compared to bupivacaine 5 mg/mL. In 1 study, patients underwent axillary brachial plexus block using injections of 40 mL (300 mg) of NAROPIN, 7.5 mg/mL (0.75%) or 40 mL injections of bupivacaine, 5 mg/mL (200 mg). In a second study, patients underwent subclavian perivascular brachial plexus block using 30 mL (225 mg) of NAROPIN, 7.5 mg/mL (0.75%) or 30 mL of bupivacaine 5 mg/mL (150 mg). There was no significant difference between the NAROPIN and bupivacaine groups in either study with regard to onset of anesthesia, duration of sensory blockade, or duration of anesthesia. 

The median duration of anesthesia varied between 11.4 and 14.4 hours with both techniques. In one study, using the axillary technique, the quality of analgesia and muscle relaxation in the NAROPIN group was judged to be significantly superior to bupivacaine by both investigator and surgeon. However, using the subclavian perivascular technique, no statistically significant difference was found in the quality of analgesia and muscle relaxation as judged by both the investigator and surgeon. The use of NAROPIN 7.5 mg/mL for block of the brachial plexus via either the subclavian perivascular approach using 30 mL (225 mg) or via the axillary approach using 40 mL (300 mg) both provided effective and reliable anesthesia.
Participants will receive a single oral dose of suvorexant (Treatment Y) in qualification period 1, followed by single oral dose of placebo (Treatment X) in qualification period 2 and then single oral dose of zolpidem (Treatment Z) in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
This group (Group A; Labetalol) receiveD intravenous(IV) labetalol manufactured by Zafa pharmaceutical, 50mg/10 ml ampoule) bolus doses administered over 2 minutes, at 10 minutes interval. Initially dose of 20 mg wAS administered, and if required repeated in increments of 40 mg,80 mg,80 mg,80 mg every 10 minutes till SBP became \<160 and DBP \<110 mm Hg, upto a maximum cululative dose of 300mg(total 5 bolus doses).During this time pulse and blood pressure were checked every 10 minutes.
Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment.
Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
In a controlled pharmacokinetic study, elderly subjects (greater than 65 years) compared to young adults had similar plasma concentrations of hydrocodone [see Clinical Pharmacology (12.3)]. Of the 1827 subjects exposed to hydrocodone bitartrate extended-release tablets in the pooled chronic pain studies, 241 (13%) were age 65 and older (including those age 75 and older), while 42 (2%) were age 75 and older. In clinical trials with appropriate initiation of therapy and dose titration, no untoward or unexpected adverse reactions were seen in the elderly patients who received hydrocodone bitartrate extended-release tablets. 

In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. 

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of hydrocodone bitartrate extended-release tablets slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.8)]. 

Hydrocodone is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.
INTRODUCTION: Various Machine Learning (ML) models have been used to predict sepsis-associated mortality. We conducted a systematic review to evaluate the methodologies employed in studies to predict mortality among patients with sepsis.
METHODS: Following a pre-established protocol registered at the International Prospective Register of Systematic Reviews, we performed a comprehensive search of databases from inception to February 2024. We included peer-reviewed articles reporting predicting mortality in critically ill adult patients with sepsis.
RESULTS: Among the 1822 articles, 31 were included, involving 1,477,200 adult patients with sepsis. Nineteen studies had a high risk of bias. Among the diverse ML models, Logistic regression and eXtreme Gradient Boosting were the most frequently used, in 22 and 16 studies, respectively. Nine studies performed internal and external validation. Compared with conventional scoring systems such as SOFA, the ML models showed slightly higher performance in predicting mortality (AUROC ranges: 0.62-0.90 vs. 0.47-0.86).
CONCLUSIONS: ML models demonstrate a modest improvement in predicting sepsis-associated mortality. The certainty of these findings remains low due to the high risk of bias and significant heterogeneity. Studies should include comprehensive methodological details on calibration and hyperparameter selection, adopt a standardized definition of sepsis, and conduct multicenter prospective designs along with external validations.
Although considered a rare type of cancer with an incidence under 6 cases for 100 000 persons, the thyroid carcinoma is the most frequent endocrine tumor. The incidence of this malignant disease has exponentially increased in the last decade, so that many specially centers in the world have focused on a better strategy of diagnosis, of treatment and of monitoring. By applying a suitable multimodal treatment, the prognosis of this disease is excellent, offering the patients a survival rate of over 90% at 10 years. During the monitoring of the disease, the patients are periodically supposed to withdraw the hormone treatment; because of this hormone imbalance, there will be important changes of the metabolism, especially the lipid one. This is the reason why we are preoccupied to increase the quality of life of the patients addicted to a chronic thyroid hormone therapy. The aim of this study is to demonstrate the way in which the lipid profile is influenced and to quantify the cardiovascular risk for the patients radically treated of thyroid cancer, by total thyroidectomy, metabolic irradiation and undergoing a chronic thyroid hormone treatment. Nowadays, Romania is one of the countries in which these patients are supposed to be kept in a iatrogenous myxoedema, the alternative being the recombinant thyroid stimulating hormone. For the patients with the mentioned diagnosis, the lipid profile will be determined and will consist of the following: total serologic cholesterol, cholesterol fractions, triglycerides and C reactive protein highly sensitive (hsCRP). A score for the cardiovascular accident risk will be elaborated. The attempt of classifying in cardiovascular risk groups the patients through the present study, would facilitate the selection of the patients and their access to therapies and modern monitoring strategies.
PROBLEM TO BE SOLVED: To obtain an apparatus which is suitable for transplanting an ionophore into the body of the mammals by a method wherein amphipatic molecules and receptor molecules which are aggregated and arranged are contained in a membrane which covers the surface of the apparatus. SOLUTION: An apparatus is surrounded by a membrane 10 which comprises an arrangement in which amphipatic molecules 13 are aggregated densely. At least a part of the amphipatic molecules 13 contains receptor molecules 16 which are coupled to a support. The receptor molecules 16 comprise a receptor part, and the molecules are selected from an antibody and an antibody fragment. The support is selected from a group composed of a lipid head-part group, a hydrocarbon chain, cross-linkable molecules and a membrane protein. For example, the membrane 10 is composed of a first layer 11 and a second layer 12, and the respective layers 11, 12 are composed of an arrangement of the amphipatic molecules 13. In addition, ionophores 14 and ionophores 15 are formed on the respective layers 11, 12. Terminals of the ionophores 15 are bonded to the receptor molecules 16 via linker groups 26.  Since the ionophores 14, 15 are arranged longitudinally so as to form a channel, ions can pass the membrane 10.
Subjects were patch tested with an experimental allergen panel containing ascending doses of Lyral (0.10 mg/cm2, 0.20 mg/cm2 and 0.40 mg/cm2) and a negative control. A second panel containing 20 mg of 5% Lyral in petrolatum was applied for evaluation of concordance. The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of \>=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
The invention discloses a fault diagnosis method and a fault diagnosis system for a self-help physical examination machine, which relate to the technical field of digital information transmission, and the method comprises the following steps: the self-help physical examination machine is built by establishing a combined database, and the combined database is built by updating the trusted data of the same model in real time. And carrying out data tag segmentation on the combined database to construct a fault prediction network. And configuring a basic data capturing period, carrying out data acquisition of the target self-help physical examination machine through the acquisition node, and synchronously establishing an environment data set. And inputting the data acquisition result and the environment data set into a fault prediction network, and establishing a fault focusing window. And carrying out additional data acquisition on the target self-help physical examination machine through the fault attention window, and synchronizing an additional data acquisition result to a fault prediction network so as to generate a fault prediction result by the fault prediction network. The technical problems that equipment faults of a self-help physical examination machine in the prior art are difficult to acquire in time, equipment service is interrupted, and physical examination results of users are inaccurate are solved.
The invention relates to antibodies against the receptor of insulin-like factor, which are high affinity human antibodies. They find application in the medical field and are used for treating diseases in subjects with disorders, such as short stature, weakness, osteoporosis, reduced muscle mass, neuropathy or diabetes. They are used to provide an isolated antibody or antigen-binding portion thereof that binds IGF-IR of a primate and human, preferably one that is human antibody. In particular the invention provides an anti- IGF-IR antibody, which inhibits the binding of IGF-I or IGF-II to IGF-IR, and also provides an anti- IGF-IR that activates IGF-IR. The monoclonal antibody or antigen-binding portion thereof specifically binds the human receptor of insulin-like growth factor I (IGF-IR),wherein the said antibody comprises the three CDR amino acid sequences of the variable domain of the light chain, including the amino acid sequence of SEQ ID NO: 24. In a preferred embodiment the antibody is human antibody. The invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding portion thereof and pharmaceutically acceptable carrier. A method for producing the antibody, an isolated cell line, an isolated nucleic acid molecule, a vector comprising the nucleic acid molecule, host cell and use of the antibodies, are also provided.
Five individuals who meet the eligibility criteria will take part in this study. They will have a variety of assessments performed throughout the treatment period in order to evaluate both dermatomyositis and calcinosis severity and their potential response to fractional carbon dioxide and sodium thiosulfate treatment. A medical history will be taken and baseline assessments will be performed during the screening period. Serum creatinine kinase levels will be determined on this visit and repeated at the end of the study (week 20); these levels will be one measure of monitoring disease activity during the study. One calcinosis lesion will be treated, assessed, and followed. If a second calcinosis lesion is present, it will act as a control (not treated). Two weeks prior to the first treatment session, an optional (not required) skin biopsy of the target (treated) calcinosis lesion will be offered to the the first 3 patients ≥ 18 years of age to determine optimal fractional carbon dioxide laser settings that will be used for treatment. Area and durometer (a device that measures hardness) measurements and photographs of the calcinosis lesions will be performed at weeks 0,4,8,12,16,and 20. One x-ray of the control and one x-ray of the target calcinosis lesion will also be performed during the screening period and at week 20. Assessment of muscle strength, physical functioning, endurance, and range of motion, as well as myositis activity outside of the muscles will be performed during the screening period and at weeks 8 and 20. Myositis damage assessment will be performed at the screening period and at week 20. Questionnaires to assess physical functioning pertaining to activities of daily living and quality of life, as well as the quality of life related to skin disease and the calcinosis lesions will be completed during the screening period and at weeks 8 and 20. Treatment of the target calcinosis lesion with fractional carbon dioxide laser and topical sodium thiosulfate will occur on weeks 0,2,4,6,8,10,12,14,16,and 18. Each patient will receive a total of 8-10 treatments over a 6 month period. Assessments for any side effects from the treatment will be performed prior to each treatment session on weeks 0,2,4,6,8,10,12,14,16,18, and 20.